Pfizer acquired exclusive rights to commercialize the anti-obesity drug ecnoglutide in China through an agreement with local startup Hangzhou Sciwind Bioscience.[1][2] The deal is valued at up to $495 million and includes an initial payment plus additional milestone payments.[1] The drug ecnoglutide was recently approved in China for the treatment of diabetes and is currently undergoing regulatory review for the indication of obesity.[1] The development, registration, production and supply of the drug continues to be provided by Sciwind.[1] According to Pfizer China President Jean-Christophe Pointeau, the agreement accelerates strategic planning in the field of metabolic diseases and responds to the growing needs of patients.[1] Obesity affects 14.1 percent of adults in China and is a priority of the government's Healthy China campaign.[1] Pfizer is trying to catch up with competition in the weight loss drug market, including its recent $10 billion acquisition of startup Metsera.[1]